Skip to the main content.
Other Therapy Areas

Extending our scientific depth across allergy, dermatology, ophthalmology, respiratory, women's health, and more.

Learn More →

2 min read

Why Submission Bottlenecks Matter

The period between database lock and regulatory submission is often one of the most time-sensitive stages of clinical development.

Yet for many sponsors, generating submission-ready tables, listings, and figures (TLFs) remains a significant bottleneck. Traditional workflows frequently rely on manual programming efforts that can extend timelines during a critical phase of the submission process.

Recently, Drug Discovery News highlighted Veristat's work with Clene Nanomedicine, where InStat™ helped reduce biostatistical output timelines from six weeks to one week in support of an ALS New Drug Application.

The story underscores a challenge facing many sponsors today: as studies become more complex and submission requirements continue to evolve, the ability to efficiently produce validated outputs can directly influence submission readiness.

 

Why These Delays Matter

Submission bottlenecks can affect far more than a single deliverable.

When timelines compress, delays in producing validated analyses can create downstream impacts across review processes, resource planning, and submission activities. Teams may need to reallocate resources, shorten review cycles, or delay activities dependent on finalized statistical outputs.

The impact extends beyond operational efficiency. Research cited in the Drug Discovery News article estimates that each day of delay can represent approximately $500,000 in unrealized value. While every development program is different, the finding highlights how bottlenecks in critical-path activities can influence business outcomes, development timelines, and profits.

Just as important, delays can postpone potential therapies from reaching the patients who need them.

For organizations navigating increasingly complex submissions, reducing time spent on manual programming can help maintain momentum toward key milestones while preserving the quality, traceability, and compliance required for regulatory review.

 

A Different Approach to Submission Readiness

The Veristat and Clene example illustrates what can happen when sponsors rethink traditional approaches to biostatistical outputs.

According to the article, Clene was able to reduce output timelines from six weeks to one week while managing an expanded scope of analyses during preparation for its ALS New Drug Application. Rather than becoming a bottleneck, statistical outputs were delivered in a timeframe that supported the company's submission goals.

While every program is unique, the outcome demonstrates how removing friction from the submission process can create greater flexibility when timelines are tight and requirements change.

Sponsors looking to accelerate submission readiness are increasingly focused on:

  • Reducing manual effort in the generation of submission-ready outputs
  • Improving scalability when analysis requirements expand
  • Maintaining quality, traceability, and compliance
  • Supporting faster review cycles and decision-making
  • Advancing critical milestones with greater confidence

As Kyle McBride, Vice President of AI & Innovation at Veristat, recently noted:

"While much of the industry is still working on either speed, quality, or compliance, we've solved all three."

 

From Bottleneck to Opportunity

As development timelines continue to compress, sponsors are evaluating every step in the path to submission for opportunities to improve efficiency without introducing additional risk.

The question is no longer whether submission processes can be accelerated. The question is how to do so while maintaining the rigor regulators expect.

 

As Featured In Drug Discovery News

Read how Veristat and Clene Nanomedicine reduced biostatistical output timelines from six weeks to one week and why the story is generating industry attention. 

 
 
Learn More About InStat™

Discover how InStat™ helps sponsors accelerate submission-ready outputs while maintaining quality, traceability, and compliance.


Veristat Cuts Biostat Analysis Time for Clene Nanomedicine

Clene Nanomedicine Partners with Veristat to Reduce Biostatistical Output Time by 80% for ALS New Drug Application

Read More
Veristat is Recognized on the Inc. 5000 List of America’s Fastest-Growing Private Companies for the 4th Consecutive Year

Veristat is Recognized on the Inc. 5000 List of America’s Fastest-Growing Private Companies for the 4th Consecutive Year

Veristat, a full service CRO is recognized for a 4th consecutive year by Inc. Magazine as one of the 5000 fastest-growing private companies in the...

Read More
Veristat Supported Marketing Applications for 10% of all FDA Novel Drug Approvals in 2020

Veristat Supported Marketing Applications for 10% of all FDA Novel Drug Approvals in 2020

Veristat, a scientific-minded global clinical research organization (CRO), announced today that they supported the marketing applications for 10% of...

Read More